Drug Price Trends for NEVIRAPINE ER

« Back to Dashboard

Average Pharmacy Cost for NEVIRAPINE ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Glossary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
NEVIRAPINE ER 400 MG TABLET	65862-0933-30	5.90654	EA	2018-11-21
NEVIRAPINE ER 400 MG TABLET	60505-4058-03	5.90654	EA	2018-11-21
NEVIRAPINE ER 400 MG TABLET	47781-0317-30	5.90654	EA	2018-11-21
NEVIRAPINE ER 400 MG TABLET	33342-0238-07	5.90654	EA	2018-11-21
NEVIRAPINE ER 400 MG TABLET	69097-0403-02	5.90654	EA	2018-11-21
NEVIRAPINE ER 400 MG TABLET	00378-4890-93	5.90654	EA	2018-11-21
NEVIRAPINE ER 400 MG TABLET	00781-5893-31	5.90654	EA	2018-11-21
Drug Name	NDC	Price/Unit ($)	Unit	Date

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.